Vaxcyte, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Vaxcyte, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-5.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 54% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-107.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 84% of Healthcare companies in United States.
Cash Cushion Ratio
+15%Cash, after subtracting all debt, equals 15% of its market value (net cash).
Higher than 57% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Vaxcyte, Inc. made a loss over the last year. Vaxcyte, Inc. owes $0.12 for every $1 it owns. Vaxcyte, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossVaxcyte, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.59The share price is 3.59 times Vaxcyte, Inc.'s book value per share, higher than 61% of Healthcare companies in United States.
Market cap
$9.9 BThe total market value of all of Vaxcyte, Inc.'s shares at today's price (share price × number of shares), larger than 90% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$2.8 BWhat Vaxcyte, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$17.52Net worth divided by the number of shares. The share price of $62.85 is 3.6 times this, which is the P/B above.
Return on equity (ROE)
-36.5%Vaxcyte, Inc. lost 36.5% of its shareholders' money over the last year, higher than 57% of Healthcare companies in United States.
Owes vs Owns
0.12×Vaxcyte, Inc. owes $0.12 for every $1 it owns (low), lower than 83% of Healthcare companies in United States.
Dividend yield
NoneVaxcyte, Inc. does not currently pay a dividend.
Profit growth
LossVaxcyte, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashVaxcyte, Inc. held $1.4 B more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Vaxcyte, Inc.: $9.9 B ÷ $2.8 B (30 Jun 2026) = 3.6.
What is Vaxcyte, Inc.'s return on equity?
Vaxcyte, Inc. lost 36.5% of its shareholders' money over the last year, higher than 57% of Healthcare companies in United States.
How much does Vaxcyte, Inc. owe compared with what it owns?
Vaxcyte, Inc. owes $0.12 for every $1 it owns (low), lower than 83% of Healthcare companies in United States.
Does Vaxcyte, Inc. pay a dividend?
No. Vaxcyte, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.